These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 20954340)
1. [Personalized medicine and molecular targets of drugs]. Nishiyama M Nihon Rinsho; 2010 Oct; 68(10):1917-22. PubMed ID: 20954340 [TBL] [Abstract][Full Text] [Related]
2. [Historical aspect of molecular-targeted therapy for cancer]. Sone S; Otsuka K; Tobiume M; Tada H Nihon Rinsho; 2010 Oct; 68(10):1787-95. PubMed ID: 20954319 [TBL] [Abstract][Full Text] [Related]
3. Progress towards personalized medicine. Bates S Drug Discov Today; 2010 Feb; 15(3-4):115-20. PubMed ID: 19914397 [TBL] [Abstract][Full Text] [Related]
4. [Personalized medicine--genomic phase]. Brdicka R Cas Lek Cesk; 2009; 148(10):477-80. PubMed ID: 20662409 [TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
6. [Genomic markers and anticancer chemotherapy]. Nishiyama M Gan To Kagaku Ryoho; 2008 Feb; 35(2):194-9. PubMed ID: 18281756 [TBL] [Abstract][Full Text] [Related]
7. Personalized medicine in oncology: tailoring the right drug to the right patient. Jiang Y; Wang M Biomark Med; 2010 Aug; 4(4):523-33. PubMed ID: 20701441 [TBL] [Abstract][Full Text] [Related]
8. Impact of genomics on personalized cancer medicine. Arteaga CL; Baselga J Clin Cancer Res; 2012 Feb; 18(3):612-8. PubMed ID: 22298893 [TBL] [Abstract][Full Text] [Related]
13. Group-based and personalized care in an age of genomic and evidence-based medicine: a reappraisal. Maglo KN Perspect Biol Med; 2012; 55(1):137-54. PubMed ID: 22643722 [TBL] [Abstract][Full Text] [Related]
14. [Personalized medicine in haematooncology--the pathologist's perspective]. Campr V Cas Lek Cesk; 2010; 149(10):464-7. PubMed ID: 21121135 [TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016 [TBL] [Abstract][Full Text] [Related]
16. Profiling protein expression and interactions: proximity ligation as a tool for personalized medicine. Blokzijl A; Friedman M; Pontén F; Landegren U J Intern Med; 2010 Sep; 268(3):232-45. PubMed ID: 20695973 [TBL] [Abstract][Full Text] [Related]
17. The pleomorphism of systemic sclerosis: are we ready for 'personalized medicine' in scleroderma? Steen VD Expert Rev Clin Immunol; 2011 Jul; 7(4):403-5. PubMed ID: 21790281 [No Abstract] [Full Text] [Related]
18. The personalised medicine. A paradigm of evidence-based medicine. Kumar D Ann Ist Super Sanita; 2011; 47(1):31-40. PubMed ID: 21430336 [TBL] [Abstract][Full Text] [Related]
19. Ethical and legal aspects of oncogenomics. Stankov K; Draskovic D; Mikov M J BUON; 2012; 17(2):383-8. PubMed ID: 22740222 [TBL] [Abstract][Full Text] [Related]
20. Molecular biomarkers: a US FDA effort. Hong H; Goodsaid F; Shi L; Tong W Biomark Med; 2010 Apr; 4(2):215-25. PubMed ID: 20406066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]